Roteas
Procedural steps taken and scientific information after the authorisation
Applicatio
Scope
n number
Opinion/ 
Commission 
Product 
Summary
Notification
Decision 
Information 
1 issued on
Issued2 / 
affected3 
amended 
on
WS/2409
This was an application for a variation following a 
12/10/2023
20/11/2023
SmPC, 
Following the review of paediatric data it was concluded 
worksharing procedure according to Article 20 of 
Labelling and 
that edoxaban is not recommended for use in children and 
Commission Regulation (EC) No 1234/2008.
PL
adolescents from birth to 18 years of age with confirmed 
C.I.4 - Change(s) in the SPC, Labelling or PL due to new
quality, preclinical, clinical or pharmacovigilance data
VTE (PE and/or DVT) event as the efficacy has not been 
established. Available data in VTE patients are described in 
sections 4.8, 5.1 and 5.2. For more information, please 
refer to the Summary of Product Characteristics.
PSUSA/103
Periodic Safety Update EU Single assessment - 
25/05/2023
09/08/2023
SmPC, 
Refer to Scientific conclusions and grounds recommending 
87/202210
edoxaban
Labelling and 
the variation to terms of the Marketing Authorisation(s)’ for 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures.
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us 
Send us a question  Go to www.ema.europa.eu/contact  Telephone +31 (0)88 781 6000
An agency of the European Union
WS/2510
This was an application for a variation following a 
13/07/2023
n/a
PL
PSUSA/10387/202210.
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008.
B.I.c.1.z - Change in immediate packaging of the AS - 
Other variation
WS/2483
This was an application for a variation following a 
08/06/2023
n/a
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008.
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission of 
studies to the competent authority
WS/2444
This was an application for a variation following a 
26/04/2023
n/a
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008.
B.I.a.1.g - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Introduction of a new manufacturer of the AS that is not 
supported by an ASMF and requires significant update to 
the relevant AS section in the dossier
IG/1610
B.I.a.1.a - Change in the manufacturer of AS or of a 
20/04/2023
n/a
starting material/reagent/intermediate for AS - The 
proposed manufacturer is part of the same 
pharmaceutical group as the currently approved 
manufacturer
Page 2/9
WS/2400
This was an application for a variation following a 
19/01/2023
n/a
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008.
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation
WS/2379/G
This was an application for a group of variations 
10/11/2022
n/a
following a worksharing procedure according to Article 
20 of Commission Regulation (EC) No 1234/2008.
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation
B.I.a.3.z - Change in batch size (including batch size 
ranges) of AS or intermediate - Other variation
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation
IG/1569
A.4 - Administrative change - Change in the name 
01/11/2022
n/a
and/or address of a manufacturer or an ASMF holder or 
supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient
PSUSA/103
Periodic Safety Update EU Single assessment - 
10/06/2022
n/a
PRAC Recommendation - maintenance
87/202110
edoxaban
Page 3/9
WS/2190
This was an application for a variation following a 
22/04/2022
n/a
Based on the review of data on quality, safety and efficacy, 
the CHMP considered that the benefit-risk balance of 
Roteas in the approved indication remains favourable and 
therefore recommended the renewal of the marketing 
authorisation with unlimited validity.
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008.
B.I.a.1.g - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Introduction of a new manufacturer of the AS that is not 
supported by an ASMF and requires significant update to 
the relevant AS section in the dossier
IG/1484/G
This was an application for a group of variations.
23/03/2022
n/a
B.II.b.1.b - Replacement or addition of a manufacturing 
site for the FP - Primary packaging site
B.II.b.1.a - Replacement or addition of a manufacturing 
site for the FP - Secondary packaging site
WS/2078
This was an application for a variation following a 
24/02/2022
n/a
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008.
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission of 
studies to the competent authority
R/0021
Renewal of the marketing authorisation.
14/10/2021
09/12/2021
SmPC and PL
IG/1454/G
This was an application for a group of variations.
05/11/2021
n/a
B.I.b.2.a - Change in test procedure for AS or starting 
material/reagent/intermediate - Minor changes to an 
Page 4/9
approved test procedure
B.I.b.2.a - Change in test procedure for AS or starting 
material/reagent/intermediate - Minor changes to an 
approved test procedure
PSUSA/103
Periodic Safety Update EU Single assessment - 
10/06/2021
n/a
PRAC Recommendation - maintenance
87/202010
edoxaban
IG/1364
B.I.a.1.a - Change in the manufacturer of AS or of a 
06/05/2021
n/a
starting material/reagent/intermediate for AS - The 
proposed manufacturer is part of the same 
pharmaceutical group as the currently approved 
manufacturer
WS/1895/G
This was an application for a group of variations 
26/11/2020
24/06/2021
SmPC, 
following a worksharing procedure according to Article 
20 of Commission Regulation (EC) No 1234/2008.
Labelling and 
PL
B.II.e.1.b.1 - Change in immediate packaging of the 
finished product - Change in type/addition of a new 
container - Solid, semi-solid and non-sterile liquid 
pharmaceutical forms
B.II.e.1.b.1 - Change in immediate packaging of the 
finished product - Change in type/addition of a new 
container - Solid, semi-solid and non-sterile liquid 
pharmaceutical forms
WS/1922
This was an application for a variation following a 
26/11/2020
24/06/2021
SmPC, 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008.
Labelling and 
PL
Page 5/9
C.I.4 - Change(s) in the SPC, Labelling or PL due to new 
quality, preclinical, clinical or pharmacovigilance data
WS/1760
This was an application for a variation following a 
26/11/2020
n/a
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008.
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission of 
studies to the competent authority
WS/1880
This was an application for a variation following a 
10/09/2020
n/a
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008.
B.I.a.1.a - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
proposed manufacturer is part of the same 
pharmaceutical group as the currently approved 
manufacturer
WS/1756
This was an application for a variation following a 
25/06/2020
24/06/2021
SmPC, Annex 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008.
II and PL
C.I.4 - Change(s) in the SPC, Labelling or PL due to new 
quality, preclinical, clinical or pharmacovigilance data
PSUSA/103
Periodic Safety Update EU Single assessment - 
14/05/2020
n/a
PRAC Recommendation - maintenance
87/201910
edoxaban
Page 6/9
T/0013
Transfer of Marketing Authorisation
29/11/2019
18/12/2019
SmPC, 
Labelling and 
PL
IAIN/0010
C.I.z - Changes (Safety/Efficacy) of Human and 
21/06/2019
25/07/2019
SmPC, 
Veterinary Medicinal Products - Other variation
Labelling and 
PL
PSUSA/103
Periodic Safety Update EU Single assessment - 
16/05/2019
n/a
PRAC Recommendation - maintenance
87/201810
edoxaban
PSUSA/103
Periodic Safety Update EU Single assessment - 
31/10/2018
n/a
PRAC Recommendation - maintenance
87/201804
edoxaban
IG/0990/G
This was an application for a group of variations.
30/10/2018
n/a
B.I.a.1.a - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
proposed manufacturer is part of the same 
pharmaceutical group as the currently approved 
manufacturer
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of an 
obsolete parameter)
IAIN/0006
C.I.z - Changes (Safety/Efficacy) of Human and 
03/08/2018
25/07/2019
SmPC and PL
Veterinary Medicinal Products - Other variation
PSUSA/103
Periodic Safety Update EU Single assessment - 
31/05/2018
26/07/2018
SmPC and PL
Refer to Scientific conclusions and grounds recommending 
87/201710
edoxaban
the variation to terms of the Marketing Authorisation(s)’ for 
Page 7/9
II/0003
Update of sections 4.2 and 5.1 of the SmPC in line with 
30/11/2017
26/07/2018
SmPC, 
Roteas can be initiated or continued in patients who may 
changes already introduce to Lixiana 
Labelling and 
require cardioversion. For transoesophageal 
(EMEA/H/C/002629/II/0012) in order to add information 
PL
echocardiogram (TEE) guided cardioversion in patients not 
PSUSA/10387/201710.
deriving from clinical data for the use of edoxaban as 
anticoagulant therapy for patients with non-valvular 
atrial fibrillation undergoing cardioversion. The Package 
Leaflet is updated accordingly. In addition, the 
Marketing authorisation holder (MAH) took the 
opportunity to update section 4.8 of the SmPC as per 
the requirement of the finalised 
PSUSA/00010387/201610 procedure to include 
headache, abdominal pain and dizziness with a common 
frequency as new adverse drug reactions. The MAH also 
took the opportunity to bring the PI in line with the 
latest QRD template version 10.0 and to introduce some 
editorial changes and minor corrections.
C.I.4 - Change(s) in the SPC, Labelling or PL due to new 
quality, preclinical, clinical or pharmacovigilance data
previously treated with anticoagulants, Roteas treatment 
should be started at least 2 hours before cardioversion to 
ensure adequate anticoagulation. Cardioversion should be 
performed no later than 12 hours after the dose of Roteas 
on the day of the procedure. 
For all patients undergoing cardioversion: Confirmation 
should be sought prior to cardioversion that the patient has 
taken Roteas as prescribed. Decisions on initiation and 
duration of treatment should follow established guidelines 
for anticoagulant treatment in patients undergoing 
cardioversion.
PSUSA/103
Periodic Safety Update EU Single assessment - 
30/11/2017
n/a
PRAC Recommendation - maintenance
87/201704
edoxaban
WS/1230
This was an application for a variation following a 
19/10/2017
n/a
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008.
B.II.d.1.z - Change in the specification parameters 
and/or limits of the finished product - Other variation
Page 8/9
Page 9/9
